Matching articles for "Eylea"
Issue 1751 · March 30, 2026 Free
In Brief: Aflibercept (Eylea HD) for Macular Edema Following Retinal Vein Occlusion

Eylea HD (Regeneron), which contains 8 mg of the vascular endothelial growth factor (VEGF) inhibitor aflibercept, has now been approved by the FDA for intravitreal treatment of macular edema following retinal…

Med Lett Drugs Ther. 2026 Mar 30; 68(1751):56 doi:10.58347/tml.2026.1751b
Eylea HD (Regeneron), which contains 8 mg of the vascular endothelial growth factor (VEGF) inhibitor aflibercept, has now been approved by the FDA for intravitreal treatment of macular edema following retinal vein occlusion (RVO). A 2-mg dose of aflibercept (Eylea) was approved previously for this indication. Eylea and Eylea HD are also approved for treatment of neovascular (wet) age-related macular degeneration, diabetic macular edema, and diabetic retinopathy.
Issue 1719 · January 6, 2025
Drugs for Age-Related Macular Degeneration

Age-related macular degeneration (AMD) has two major forms: dry or non-neovascular (~90% of patients) and wet or neovascular (~10% of patients).

Med Lett Drugs Ther. 2025 Jan 6; 67(1719):1-5 doi:10.58347/tml.2025.1719a
Age-related macular degeneration (AMD) has two major forms: dry or non-neovascular (~90% of patients) and wet or neovascular (~10% of patients).
Issue 1719 · January 6, 2025
Drugs for Age-Related Macular Degeneration

Age-related macular degeneration (AMD) has two major forms: dry or non-neovascular (~90% of patients) and wet or neovascular (~10% of patients).

Med Lett Drugs Ther. 2025 Jan 6; 67(1719):1-5 doi:10.58347/tml.2025.1719a
Age-related macular degeneration (AMD) has two major forms: dry or non-neovascular (~90% of patients) and wet or neovascular (~10% of patients).
Issue 1649 · May 2, 2022
A Ranibizumab Ocular Implant (Susvimo) for Age-Related Macular Degeneration

The FDA has approved Susvimo (Genentech), a refillable permanent ocular implant containing the vascular endothelial growth factor (VEGF) inhibitor ranibizumab, for treatment of neovascular (wet) age-related…

Med Lett Drugs Ther. 2022 May 2; 64(1649):71-2
The FDA has approved Susvimo (Genentech), a refillable permanent ocular implant containing the vascular endothelial growth factor (VEGF) inhibitor ranibizumab, for treatment of neovascular (wet) age-related macular degeneration (nAMD) in patients who have previously responded to at least two intravitreal injections of a VEGF inhibitor. Ranibizumab intravitreal injection (Lucentis) has been available since 2006 for monthly treatment of nAMD. The FDA has approved ranibizumab-nuna (Byooviz) , a biosimilar of Lucentis and the first ophthalmologic biosimilar; it will be available in June 2022.
Issue 1646 · March 21, 2022
Faricimab (Vabysmo) for Age-Related Macular Degeneration and Diabetic Macular Edema

Faricimab-svoa ( Vabysmo – Genentech), an inhibitor of both vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang-2), has been approved by the FDA for intravitreal treatment of neovascular (wet)…

Med Lett Drugs Ther. 2022 Mar 21; 64(1646):45-6
Faricimab-svoa ( Vabysmo – Genentech), an inhibitor of both vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang-2), has been approved by the FDA for intravitreal treatment of neovascular (wet) age-related macular degeneration (nAMD) and diabetic macular edema (DME). It is the first drug to become available in the US that targets two pathways involved in maintaining vascular homeostasis. Several VEGF inhibitors are available for treatment of nAMD and DME (see Table 2).
Issue 1591 · February 10, 2020
Brolucizumab (Beovu) for Age-Related Macular Degeneration

Brolucizumab-dbll ( Beovu — Novartis), a vascular endothelial growth factor (VEGF) inhibitor, has been approved by the FDA as an intravitreal injection for treatment of neovascular (wet) age-related macular…

Med Lett Drugs Ther. 2020 Feb 10; 62(1591):23-4
Brolucizumab-dbll ( Beovu — Novartis), a vascular endothelial growth factor (VEGF) inhibitor, has been approved by the FDA as an intravitreal injection for treatment of neovascular (wet) age-related macular degeneration (AMD). It is the fourth VEGF inhibitor to be approved in the US for this indication; bevacizumab ( Avastin , and others), a VEGF inhibitor FDA-approved for treatment of breast cancer and other malignancies, has been used off-label for this indication for years.
Issue 1586 · December 2, 2019
Drugs for Common Eye Disorders

This issue includes reviews of drugs for glaucoma, age-related macular degeneration (AMD), bacterial conjunctivitis, and dry eye disease. Allergic conjunctivitis is reviewed in a separate issue.

Med Lett Drugs Ther. 2019 Dec 2; 61(1586):187-94
This issue includes reviews of drugs for glaucoma, age-related macular degeneration (AMD), bacterial conjunctivitis, and dry eye disease. Allergic conjunctivitis is reviewed in a separate issue.
Issue 1464 · March 16, 2015
VEGF Inhibitors for AMD and Diabetic Macular Edema

Vascular endothelial growth factor (VEGF) is a principal mediator of neovascularization in wet age-related macular degeneration (AMD) and diabetic macular edema. It induces angiogenesis and increases vascular…

Med Lett Drugs Ther. 2015 Mar 16; 57(1464):41-2
Vascular endothelial growth factor (VEGF) is a principal mediator of neovascularization in wet age-related macular degeneration (AMD) and diabetic macular edema. It induces angiogenesis and increases vascular permeability and inflammation. VEGF inhibitors reduce leakage from blood vessels, prevent proliferation of new abnormal vessels, decrease swelling of the retina, and improve visual acuity in patients with neovascular (wet) AMD and diabetic macular edema. These drugs are given as periodic intravitreal injections with topical anesthesia.
Issue 1415 · April 29, 2013
Ziv-Aflibercept (Zaltrap) for Metastatic Colorectal Cancer (online only)

Ziv-aflibercept ( Zaltrap – Sanofi/Regeneron), a vascular endothelial growth factor (VEGF) inhibitor, has been approved by the FDA for use in combination with 5-fluorouracil, leucovorin and irinotecan…

Med Lett Drugs Ther. 2013 Apr 29; 55(1415):36
Ziv-aflibercept ( Zaltrap – Sanofi/Regeneron), a vascular endothelial growth factor (VEGF) inhibitor, has been approved by the FDA for use in combination with 5-fluorouracil, leucovorin and irinotecan (FOLFIRI) for treatment of metastatic colorectal cancer that is resistant to or has progressed following an oxaliplatin-containing regimen. It is the same drug as aflibercept, which was approved last year as an intravitreal injection (Eylea) for treatment of neovascular (wet) agerelated macular degeneration (AMD). Ziv-aflibercept is the second VEGF inhibitor approved for treatment of metastatic colorectal cancer; bevacizumab (Avastin) , given in addition to chemotherapy, is a standard firstand second-line therapy.
Issue 123 · November 1, 2012
Drugs for Some Common Eye Disorders

Drugs for glaucoma, age-related macular degeneration, bacterial conjunctivitis, and dry eyes are reviewed here. Drugs for the treatment of allergic conjunctivitis will be reviewed in a future issue of…

Treat Guidel Med Lett. 2012 Nov; 10(123):79-86
Drugs for glaucoma, age-related macular degeneration, bacterial conjunctivitis, and dry eyes are reviewed here. Drugs for the treatment of allergic conjunctivitis will be reviewed in a future issue of Treatment Guidelines on Drugs for Allergic Disorders.
Issue 1383 · February 6, 2012
Aflibercept (Eylea) for Age-Related Macular Degeneration

The FDA has approved aflibercept (a flib’ er sept; Eylea – Regeneron) for treatment of neovascular (wet) age-related macular degeneration (AMD).

Med Lett Drugs Ther. 2012 Feb 6; 54(1383):9-10
The FDA has approved aflibercept (a flib’ er sept; Eylea – Regeneron) for treatment of neovascular (wet) age-related macular degeneration (AMD).